An Intervention Study to Reduce Drug-related Problems and Readmissions Among Old People With Dementia

NCT ID: NCT01504672

Last Updated: 2021-11-09

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

460 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2015-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this randomized controlled study is to investigate if medication reviews performed by a clinical pharmacist as part of a ward team can reduce drug related problems and reduce readmissions to hospital among elderly patients (≥65 years) with dementia and cognitive failure.

Four hundred and sixty patients will be recruited and randomized to control (usual care) and intervention group (enhanced service in which a pharmacist is part of the health care team).

Six months after the last patient of the 460 has been discharged the study will be closed. Data about the number of readmissions and visits to the emergency room will be collected during the six-month follow-up and also, the costs associated with each visit or admission. Time until institutionalization will be compared between intervention group and control group.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cognitive Impairment

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Drug related problems

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Medication review

Group Type EXPERIMENTAL

Medication review

Intervention Type OTHER

In the intervention, the pharmacist will evaluate:

* Is there an indication for the drug?
* Has the drug desired effect?
* Is the dose correct and dosing scheme correct?
* Side effects, contraindications, inappropriate drugs
* Interactions
* Treatment time
* Cost effectiveness
* Adherence to recommendation list
* Problems with handling the drugs (for example crushing of the tablets)
* Untreated indication
* Double medications
* Administration of drugs

Usual care

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Medication review

In the intervention, the pharmacist will evaluate:

* Is there an indication for the drug?
* Has the drug desired effect?
* Is the dose correct and dosing scheme correct?
* Side effects, contraindications, inappropriate drugs
* Interactions
* Treatment time
* Cost effectiveness
* Adherence to recommendation list
* Problems with handling the drugs (for example crushing of the tablets)
* Untreated indication
* Double medications
* Administration of drugs

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with dementia or cognitive impairment
* Patients ≥ 65 years

Exclusion Criteria

* Patients previously admitted to the study wards during the study period
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Umeå University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hugo Lovheim

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hugo Lövheim, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Umeå University, Umeå, Sweden

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

County hospital of Skellefteå

Skellefteå, , Sweden

Site Status

Umeå University Hospital

Umeå, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

References

Explore related publications, articles, or registry entries linked to this study.

Gustafsson M, Sjolander M, Pfister B, Jonsson J, Schneede J, Lovheim H. Pharmacist participation in hospital ward teams and hospital readmission rates among people with dementia: a randomized controlled trial. Eur J Clin Pharmacol. 2017 Jul;73(7):827-835. doi: 10.1007/s00228-017-2249-8. Epub 2017 Apr 8.

Reference Type DERIVED
PMID: 28391409 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UmU-2011-148-31M

Identifier Type: -

Identifier Source: org_study_id